Drug Information

Drug General Information
Drug ID
D01RNL
Former ID
DIB001055
Drug Name
Lintuzumab
Synonyms
Zamyl; HuM195; HuM195, PDL; Humanized M195, PDL; KB-195; SGN-33; SMART M195, PDL; M195 (humanized), Protein Design Labs; Anti-CD33 mAb (leukemia), Seattle Genetics
Drug Type
Antibody
Indication Leukemia [ICD9: 208.9; ICD10:C90-C95] Discontinued in Phase 2 [542898], [547399]
Company
PDL BioPharma Inc; Seattle Genetics
CAS Number
CAS 166089-32-3
Target and Pathway
Target(s) Myeloid cell surface antigen CD33 Target Info [527596]
KEGG Pathway Hematopoietic cell lineage
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 542898(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7983).
Ref 547399Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015937)
Ref 527596Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005 Jun 20;23(18):4110-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.